Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas

Daniel Schramek, Ataman Sendoel, Jeremy P. Segal, Slobodan Beronja, Evan Heller, Daniel Oristian, Boris Reva, Elaine Fuchs

Research output: Contribution to journalArticlepeer-review

205 Scopus citations

Abstract

Mining modern genomics for cancer therapies is predicated on weeding out "bystander" alterations (nonconsequential mutations) and identifying "driver" mutations responsible for tumorigenesis and/or metastasis. We used a direct in vivo RNA interference (RNAi) strategy to screen for genes that upon repression predispose mice to squamous cell carcinomas (SCCs). Seven of our top hits - including Myh9, which encodes nonmuscle myosin IIa - have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. In human and mouse keratinocytes, myosin IIa's function is manifested not only in conventional actin-related processes but also in regulating posttranscriptional p53 stabilization. Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalScience
Volume343
Issue number6168
DOIs
StatePublished - 2014

Fingerprint

Dive into the research topics of 'Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas'. Together they form a unique fingerprint.

Cite this